Veru Revenue and Competitors

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Veru's estimated annual revenue is currently $18.8M per year.(i)
  • Veru's estimated revenue per employee is $155,000

Employee Data

  • Veru has 121 Employees.(i)

Veru's People

NameTitleEmail/Phone
1
Chairman, CEO, and PresidentReveal Email/Phone
2
Chief Business OfficerReveal Email/Phone
3
Chief Scientific OfficerReveal Email/Phone
4
Vice Chairman, Chief Corporate OfficerReveal Email/Phone
5
CFO and CAOReveal Email/Phone
6
EVP, Global Clinical OperationsReveal Email/Phone
7
EVP - Deputy General CounselReveal Email/Phone
8
VP Head Medical AffairsReveal Email/Phone
9
EVPReveal Email/Phone
10
Head Quality Assurance, North AmericaReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$99.4M45840%N/AN/A
#2
$20.6M13322%N/AN/A
#3
$156.1M146-70%$145MN/A
#4
$3.5M45-25%$150MN/A
#5
$1.6M210%$459.5MN/A
#6
$67.3M31016%$180.7MN/A
#7
$8.5M55-2%N/AN/A
#8
$256.3M10259%$168.5MN/A
#9
$2.8M18-33%N/AN/A
#10
$9.1M59-9%N/AN/A
Add Company

What Is Veru?

keywords:N/A

N/A

Total Funding

121

Number of Employees

$18.8M

Revenue (est)

N/A

Employee Growth %

N/A

Valuation

N/A

Accelerator

Veru News

2022-04-17 - Is Veru Stock a Buy Now?

Veru (NASDAQ: VERU) is a bit of an oddball in biotech. It's developing medicines for breast cancer and treatment-resistant prostate cancer,...

2022-04-13 - Veru Stock Could Hit $36, Says Oppenheimer

Avid stock market watchers will know the biotech space operates according to a different rule set. One session can wipe off a huge chunk of...

2022-04-06 - Veru's Novel COVID-19 Drug Candidate Reduces Deaths by 55% in Hospitalized Patients in Interim Analysis of Phase ...

Independent Data Monitoring Committee Unanimously Recommends that Phase 3 Clinical Trial for Sabizabulin for Treatment of Hospitalized...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$18.4M12114%$68M
#2
$36.9M12149%N/A
#3
$25.4M12119%N/A
#4
$16.9M121-2%N/A
#5
$39.3M12114%N/A